Clinical trials: Sleepiness
Cognitive Dysfunction
Aprepitant to Mitigate Opioids' Cognitive Side Effects
Morphine and similar substances (called opioids) are often prescribed for moderate to severe pain, such as after a surgery, thus allowing for minimal pain and a better recovery.
- Trial name
- NCT02226601
- Testing
- Aprepitant
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Narcolepsy Type 1, Hypnagogic Hallucinations
Imagery Control Therapy and Lucid Dreaming for REM-Related Symptoms in Narcolepsy
This randomized controlled trial evaluated the efficacy of a cognitive behavioral intervention based on lucid dreaming training and imagery control therapy for reducing REM-related symptoms in patients with narcolepsy type 1.
- Conditions
- Narcolepsy Type 1, Hypnagogic Hallucinations, Sleep Paralysis, REM Sleep Intrusion Symptoms
- Trial name
- ICLDR-NAR Tria (NCT07609537)
- Testing
- Cognitive Behavioral Therapy for Narcolepsy (CBT-NAR) With Lucid Dreaming and Imagery Control Therapy, Sleep Hygiene Education and Structured Clinical Follow-up
- Where
- Colombia
- Volunteers
- 98 people
- Sponsor
- Institute of Behavioral Sleep Medicine, Colombia
Narcolepsy, Cataplexy Narcolepsy
Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)
CONCERT (Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment) is a Phase 2, double-blind, randomized, placebo-controlled, crossover, multicenter trial of AXS-12 in patients with narcolepsy.
- Conditions
- Narcolepsy, Cataplexy Narcolepsy, Excessive Sleepiness
- Trial name
- CONCERT (NCT03881852)
- Testing
- AXS-12 (Reboxetine)
- Where
- 14 sites in United States
- Volunteers
- 21 people
- Sponsor
- Axsome Therapeutics, Inc.
Parkinson Disease, Mild Cognitive Impairment
Auditory Slow Wave Enhancement in Parkinson Disease and Mild Cognitive Impairment
The study aims to assess the efficacy of auditory slow-wave sleep (SWS) enhancement in PD patients and patients with amnestic MCI.
- Trial name
- PDMCI-TS (NCT04736017)
- Testing
- TSB Axo
- Where
- Switzerland
- Volunteers
- 48 people
- Sponsor
- University of Zurich
Narcolepsy
Expanded Access to SUVN-G3031 (Samelisant) for the Treatment of Subjects With Narcolepsy
The study is planned to provide expanded access treatment to subjects with narcolepsy who have completed the 2-week treatment phase and follow-up in study CTP2S13031H3 (NCT04072380), and in instances when the investigator as well…
- Trial name
- NCT05530447
- Testing
- Samelisant
- Sponsor
- Suven Life Sciences Limited
Insomnia
Digital Sleep Program for College Students with Insomnia
This randomized controlled trial (RCT) study aims to evaluate the effectiveness of a digital-based multimodal sleep management program compared to a waitlist control group in improving sleep-related outcomes, including insomnia…
- Trial name
- DSP-CS (NCT06853106)
- Testing
- Waitlist control group, digital-based multimodal sleep management program
- Where
- Taiwan
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Taipei Medical University
Narcolepsy, Sleep Apnea, Obstructive
PROVIGIL® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome
The primary objective of the study is to evaluate the safety and tolerability of treatment with PROVIGIL in children and adolescents with excessive sleepiness (ES) associated with narcolepsy or OSAHS (obstructive sleep…
- Trial name
- NCT00107848
- Testing
- Modafinil
- Where
- 61 sites in United States, Canada
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Cephalon
Narcolepsy, Idiopathic Hypersomnia
Cardiovascular and Cognitive Implications of Central Disorders of Hypersomnolence and Their Treatments
This is an observational study evaluating patients diagnosed with narcolepsy or idiopathic hypersomnia that have been prescribed a new/different hypersomnia treatment.
- Trial name
- NCT05371483
- Testing
- 24-hour Ambulatory Blood Pressure Monitoring, Oculo-Cognitive Addition Test (OCAT)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Parkinson's Disease
Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease
To compare the efficacy of BF2.649 over placebo (12 week Double-Blind Phase) and assess the long term safety and the efficacy maintenance(9 months Open-Label Extension Phase) of BF2.649 in the improvement of excessive daytime…
- Trial name
- HARPS2 (NCT01066442)
- Testing
- BF2.649 (Pitolisant)
- Where
- Germany
- Volunteers
- 273 people
- Sponsor
- Bioprojet
Excessive Daytime Somnolence, Sleep Deprivation
Start Times and Restful Sleep
The purpose of this study is to evaluate the efficacy of later school start times in increasing student sleep, and examine the association between later start times and physical activity, screen time, and commute time.
- Trial name
- STaRtS (NCT04049682)
- Testing
- Delayed School Start Time
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of California, San Diego
Narcolepsy, Amyloid Pathology
Narcolepsy Protect Against Alzheimer's Disease?
Links between orexin and amyloid processes have been underlined recently. During the Alzheimer's process an upregulation of the orexin mechanism has been observed.
- Trial name
- PROTECMAN (NCT03378453)
- Testing
- PET-scan18F-AV-45
- Where
- France
- Volunteers
- 38 people
- Sponsor
- University Hospital, Montpellier
Parkinson's Disease
Comparison of Modafinil and Methylphenidate in Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease
This is an open-label cross-over randomized control study comparing the effect of modafinil and methylphenidate in patients with Parkinson's disease with excessive daytime sleepiness.
- Trial name
- NCT00393562
- Testing
- modafinil, methylphenidate
- Where
- United States
- Sponsor
- US Department of Veterans Affairs
Parkinson Disease
Bright Light Therapy for Non-motor Symptoms in Parkinson's Disease
This is a randomized placebo- and active-controlled trial for assessing the efficacy of bright light therapy for sleep and mood symptoms in patients with Parkinson's disease
- Trial name
- NCT05524961
- Testing
- Bright light therapy, Inactivated negative ion generator
- Where
- Hong Kong
- Volunteers
- 69 people
- Sponsor
- Chinese University of Hong Kong
Narcolepsy, Obstructive Sleep Apnea (OSA)
Study of Psychological, Sociological and Professional Factors Associated With Maintenance of Wakefulness Test
The predictors of objective impaired alertness assessed by Maintenance of Wakefulness Tests (MWT) are poorly understood. Identifying such predictors are essential from a clinical point of view and from a pathophysiological…
- Trial name
- STAYAWAKE (NCT06586138)
- Testing
- STAI (State-Trait Anxiety Inventory) Scale : Psychological inventory of 20 self-report items on a 4-point scale
- Where
- France
- Volunteers
- 103 people
- Sponsor
- Hospices Civils de Lyon
Idiopathic Hypersomnia
A Study of TAK-360 in Adults With Idiopathic Hypersomnia
Idiopathic Hypersomnia (IH) is a condition where people feel extremely sleepy during the day, especially in the morning, even if they sleep a lot at night.
- Trial name
- NCT06812078
- Testing
- TAK-360
- Where
- 29 sites in United States, France and 4 more
- Volunteers
- 96 people
- Sponsor
- Takeda
Depression, Excessive Daytime Sleepiness
Sedating Antidepressant Improves Driving Safety in Patients With Major Depressive Disorder
This concurrent, two-part study will: I) Using overnight sleep recordings, evaluate the short- and long-term sleep-promoting effects of the antidepressant mirtazapine (Remeron) in patients who have been prescribed this medication…
- Trial name
- NCT00385437
- Testing
- Driving Simulator Testing, Mirtazapine Treatment
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- University Health Network, Toronto
Excessive Daytime Sleepiness, Obstructive Sleep Apnea
Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness
The first objective of this study is to demonstrate the efficacy and safety of pitolisant given at 10, 20, or 40 mg per day versus placebo during 12 weeks of the Double Blind period, to treat the Excessive Daytime Sleepiness…
- Trial name
- HAROSA IV (NCT02978651)
- Testing
- Pitolisant (BF2.649)
- Where
- 2 sites in France
- Sponsor
- Bioprojet
Heart Failure, Insomnia
Cognitive Behavioral Therapy for Insomnia in Stable Heart Failure
The purpose of this exploratory developmental study is to test the feasibility, acceptability, and preliminary efficacy of cognitive behavioral therapy for insomnia (CBT-I) among adults who have stable Heart Failure.
- Conditions
- Heart Failure, Insomnia, Cardiomyopathy
- Trial name
- CBTI-HF (NCT02827799)
- Testing
- Cognitive Behavioral Therapy for Insomnia (CBT-I), Heart Failure Self-Management Education
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Yale University
Narcolepsy
Genetic and Clinical Characterization of Type 1 and 2 Narcolepsy in Adult and Pediatric Black and North African Populations
Narcolepsy type 1 (NT1) is a neurological disorder characterized by excessive daytime sleepiness, cataplexy, sleep paralysis, and hallucinations while awake.
- Trial name
- NarcoGen (NCT06786377)
- Testing
- saliva sampling
- Where
- France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Obstructive Sleep Apnoea, Excessive Daytime Sleepiness
Dose-range Finding Study of BF2.649 Effect on Patients With Obstructive Sleep Apnea (OSA)
Prospective, multicenter, double-blind, phase II, randomized, dose-response study in 5 parallel groups (dose-range).
- Trial name
- NCT01620554
- Testing
- BF2.649
- Where
- France
- Volunteers
- 110 people
- Sponsor
- Bioprojet